John B. Bode's most recent trade in Zevra Therapeutics Inc was a trade of 5,000 Common Stock done at an average price of $9.2 . Disclosure was reported to the exchange on Aug. 19, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Zevra Therapeutics Inc | John B. Bode | Director | Purchase of securities on an exchange or from another person at price $ 9.16 per share. | 19 Aug 2025 | 5,000 | 45,000 (0%) | 0% | 9.2 | 45,825 | Common Stock |
| Zevra Therapeutics Inc | John B. Bode | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Zevra Therapeutics Inc | John B. Bode | Director | Purchase of securities on an exchange or from another person at price $ 7.96 per share. | 19 Mar 2025 | 10,000 | 40,000 (0%) | 0% | 8.0 | 79,624 | Common Stock |
| Zevra Therapeutics Inc | John B. Bode | Director | Purchase of securities on an exchange or from another person at price $ 5.87 per share. | 12 Jul 2024 | 10,000 | 30,000 (0%) | 0% | 5.9 | 58,661 | Common Stock |
| Zevra Therapeutics Inc | John B. Bode | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 39,200 | 39,200 | - | - | Stock Option (right to buy) | |
| Zevra Therapeutics Inc | John B. Bode | Director | Purchase of securities on an exchange or from another person at price $ 5.04 per share. | 18 May 2023 | 4,759 | 7,449 (0%) | 0% | 5.0 | 23,985 | Common Stock |
| Zevra Therapeutics Inc | John B. Bode | Director | Purchase of securities on an exchange or from another person at price $ 5.05 per share. | 18 May 2023 | 2,451 | 10,000 (0%) | 0% | 5.1 | 12,378 | Common Stock |
| Zevra Therapeutics Inc | John B. Bode | Director | Purchase of securities on an exchange or from another person at price $ 5.04 per share. | 18 May 2023 | 1,390 | 1,390 (0%) | 0% | 5.0 | 6,999 | Common Stock |
| Zevra Therapeutics Inc | John B. Bode | Director | Purchase of securities on an exchange or from another person at price $ 5.04 per share. | 18 May 2023 | 1,000 | 2,690 (0%) | 0% | 5.0 | 5,040 | Common Stock |
| Zevra Therapeutics Inc | John B. Bode | Director | Purchase of securities on an exchange or from another person at price $ 5.04 per share. | 18 May 2023 | 300 | 1,690 (0%) | 0% | 5.0 | 1,512 | Common Stock |
| Zevra Therapeutics Inc | John B. Bode | Director | Purchase of securities on an exchange or from another person at price $ 5.05 per share. | 18 May 2023 | 100 | 7,549 (0%) | 0% | 5.1 | 505 | Common Stock |
| Zevra Therapeutics Inc | John B. Bode | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 58,800 | 58,800 | - | - | Stock Option (right to buy) |